ReviewJournal of the American College of Cardiology2021
New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4.
Review in Journal of the American College of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- The Potential Cardiometabolic Effects of Long-Chain ω-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies.Advances in nutrition (Bethesda, Md.) · 2023Pooled it
- Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials.Cardiovascular drugs and therapy · 2025Trial
- Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.Nature medicine · 2023Trial
- Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations.JCI insight · 2022Trial
- Review
- Association Between Remnant Cholesterol and Muscle Mass and Quality: Insights from Muscle Quality Mapping and Abdominal Computed Tomography.Diagnostics (Basel, Switzerland) · 2026Article
- Association of triglyceride-driven residual atherosclerotic risk with carotid stiffening assessed using ultrafast ultrasound imaging in individuals with hypertriglyceridemia.Ultrasonography (Seoul, Korea) · 2026Article
- Beyond Fasting Lipids: Nutritional and Clinical Perspectives on Postprandial Triglycerides.Nutrients · 2026Review
- The Role of Triglycerides in the Development of Atherosclerosis.Acta medica Lituanica · 2026Review
- Editorial: Proteomics in atherosclerosis.Frontiers in cardiovascular medicine · 2026Article
- Nonlinear and Age-Specific Associations Between Atherogenic Index of Plasma and Differential Cardiovascular Risk Profiles in US Adults.Cardiovascular therapeutics · 2026Article
- The impact of olezarsen on hypertriglyceridemia in high cardiovascular risk patients: a systematic review, meta-analysis, and meta-regression.Annals of medicine and surgery (2012) · 2025Article
- Remnant cholesterol is associated with unstable carotid plaque in a neurologically healthy population.Stroke and vascular neurology · 2025Article
- Fatty Acid Esterification of Octacosanol Attenuates Triglyceride and Cholesterol Synthesis in Mice.Journal of agricultural and food chemistry · 2025Article
- The Emerging Potential of Apolipoprotein C-III Inhibition for ASCVD Prevention: A State-of-the-Art Review.Current atherosclerosis reports · 2024Review
- Mechanisms of Abnormal Lipid Metabolism in the Pathogenesis of Disease.International journal of molecular sciences · 2024Review
- New approaches to triglyceride reduction: Is there any hope left?American journal of preventive cardiology · 2024Article
- Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling.Clinical proteomics · 2024Review
- Triglyceride-rich lipoproteins and cardiovascular diseases.Frontiers in endocrinology · 2024Review
- Association of remnant cholesterol with sarcopenia in Korean adults: a nationwide population-based study using data from the KNHANES.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Emerging evidence suggests that elevated concentrations of triglyceride-rich lipoprotein remnants (TRLs) derived from hepatic and intestinal sources contribute to the risk of atherosclerotic cardiovascular events. Natural selection studies support a causal role for elevated concentrations of remnant cholesterol and the pathways contributing to perturbations in metabolic pathways regulating TRLs with an increased risk of atherosclerotic cardiovascular disease events. New therapies targeting select catalytic pathways in TRL metabolism reduce atherosclerosis in experimental models, and concentrations of TRLs in patients with a vast range of triglyceride levels. Clinical trials with inhibitors of angiopoietin-like 3 protein and apolipoprotein C-III will be required to provide further guidance on the potential contribution of these emerging therapies in the paradigm of cardiovascular risk management in patients with elevated remnant cholesterol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.